A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate‐1 risk myelodysplastic syndrome
Azra Raza(University of Illinois Chicago), Mikkael A. Sekeres(University of Miami), Daruka Mahadevan(The University of Texas at San Antonio Health Science Center), Stefan Faderl(Jazz Pharmaceuticals (United States)), John E. Godwin(Providence Portland Medical Center), Deborah Mulford(University of Rochester), Dale Schaar(Merck & Co., Inc., Rahway, NJ, USA (United States)), Alan F. List(TE Laboratories (Ireland)), Naomi Galili(Columbia University Irving Medical Center), Han Myint(Denver Health Medical Center), Scott E. Smith(Loyola University Medical Center), Gail L. Brown(Palo Alto Institute), Rami S. Komrokji(Moffitt Cancer Center), Ralph V. Boccia(Center for Cancer and Blood Disorders), Mark U. Rarick(Kaiser Permanente)
Cited by 44
Related Papers
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Age and acute myeloid leukemia
|Blood|2006|1.4k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k